Cargando…

Case report: Chlorpromazine and deep venous thrombosis

PURPOSE: Since the development of antipsychotic drugs in the 1950s, a variety of studies and case reports have been published that suggest an association between exposure to typical antipsychotics and venous thromboembolisms (VTE). Therefore, when starting treatment with antipsychotics, especially l...

Descripción completa

Detalles Bibliográficos
Autores principales: Reed, Matthew Joseph, Comeau, Sean, Wojtanowicz, Todd R., Sampathi, Bharat Reddy, Penev, Sofia, Bota, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Emerald Publishing Limited 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364570/
https://www.ncbi.nlm.nih.gov/pubmed/32742621
http://dx.doi.org/10.1108/MIJ-10-2019-0005
_version_ 1783559856077144064
author Reed, Matthew Joseph
Comeau, Sean
Wojtanowicz, Todd R.
Sampathi, Bharat Reddy
Penev, Sofia
Bota, Robert
author_facet Reed, Matthew Joseph
Comeau, Sean
Wojtanowicz, Todd R.
Sampathi, Bharat Reddy
Penev, Sofia
Bota, Robert
author_sort Reed, Matthew Joseph
collection PubMed
description PURPOSE: Since the development of antipsychotic drugs in the 1950s, a variety of studies and case reports have been published that suggest an association between exposure to typical antipsychotics and venous thromboembolisms (VTE). Therefore, when starting treatment with antipsychotics, especially low-potency typical antipsychotics and clozapine, health-care providers must account for the patient’s existing VTE risk factors. DESIGN/METHODOLOGY/APPROACH: In this case report, the authors describe the development of a pulmonary embolism associated with use of chlorpromazine in the treatment of an acute manic episode in a 51-year-old female patient with bipolar disorder type 1. FINDINGS: The patient was brought to the emergency room by the police on a legal hold for bizarre behaviors at a bus stop, which included incessantly yelling at bystanders. The patient was found to have disorganized thoughts, poor sleep, rapid speech, labile mood, distractibility, auditory hallucinations and grandiose delusions. During the course of her stay, the patient received extensive IM chlorpromazine for extreme agitation, in addition to chlorpromazine 200 mg IM Q8H, which was later decreased to chlorpromazine 100 mg chlorpromazine IM/PO Q8H. On day 4 of the treatment, the patient experienced difficulty breathing, hypoxia and tachycardia and was found to have bilateral expiratory wheezes. CT angiography showed sub-segmental pulmonary embolus and the patient was transferred to MICU service. The patient was then intubated and started on heparin by the medical team. Over the course of the next day, her respiratory distress resolved and the patient was extubated. ORIGINALITY/VALUE: It is possible that chlorpromazine may indeed increase VTEs, and there are various physiological postulations regarding the mechanism of action. However, multiple confounding variables existed in the authors’ report, including venous stasis and the use of restraints, tobacco and valproic acid. Each of these variables has been shown to increase VTE occurrence. Further controlled studies are necessary to identify the true relationship between antipsychotics and VTEs.
format Online
Article
Text
id pubmed-7364570
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Emerald Publishing Limited
record_format MEDLINE/PubMed
spelling pubmed-73645702020-07-31 Case report: Chlorpromazine and deep venous thrombosis Reed, Matthew Joseph Comeau, Sean Wojtanowicz, Todd R. Sampathi, Bharat Reddy Penev, Sofia Bota, Robert Ment Illn Research Paper PURPOSE: Since the development of antipsychotic drugs in the 1950s, a variety of studies and case reports have been published that suggest an association between exposure to typical antipsychotics and venous thromboembolisms (VTE). Therefore, when starting treatment with antipsychotics, especially low-potency typical antipsychotics and clozapine, health-care providers must account for the patient’s existing VTE risk factors. DESIGN/METHODOLOGY/APPROACH: In this case report, the authors describe the development of a pulmonary embolism associated with use of chlorpromazine in the treatment of an acute manic episode in a 51-year-old female patient with bipolar disorder type 1. FINDINGS: The patient was brought to the emergency room by the police on a legal hold for bizarre behaviors at a bus stop, which included incessantly yelling at bystanders. The patient was found to have disorganized thoughts, poor sleep, rapid speech, labile mood, distractibility, auditory hallucinations and grandiose delusions. During the course of her stay, the patient received extensive IM chlorpromazine for extreme agitation, in addition to chlorpromazine 200 mg IM Q8H, which was later decreased to chlorpromazine 100 mg chlorpromazine IM/PO Q8H. On day 4 of the treatment, the patient experienced difficulty breathing, hypoxia and tachycardia and was found to have bilateral expiratory wheezes. CT angiography showed sub-segmental pulmonary embolus and the patient was transferred to MICU service. The patient was then intubated and started on heparin by the medical team. Over the course of the next day, her respiratory distress resolved and the patient was extubated. ORIGINALITY/VALUE: It is possible that chlorpromazine may indeed increase VTEs, and there are various physiological postulations regarding the mechanism of action. However, multiple confounding variables existed in the authors’ report, including venous stasis and the use of restraints, tobacco and valproic acid. Each of these variables has been shown to increase VTE occurrence. Further controlled studies are necessary to identify the true relationship between antipsychotics and VTEs. Emerald Publishing Limited 2019-11-04 /pmc/articles/PMC7364570/ /pubmed/32742621 http://dx.doi.org/10.1108/MIJ-10-2019-0005 Text en © Matthew Joseph Reed, Sean Comeau, Todd R. Wojtanowicz, Bharat Reddy Sampathi, Sofia Penev and Robert Bota. https://creativecommons.org/licenses/by/4.0/Published by Emerald Publishing Limited. This article is published under the Creative Commons Attribution (CC BY 4.0) licence. Anyone may reproduce, distribute, translate and create derivative works of this article (for both commercial and non-commercial purposes), subject to full attribution to the original publication and authors. The full terms of this licence may be seen at: http://creativecommons.org/licences/by/4.0/legalcode (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Research Paper
Reed, Matthew Joseph
Comeau, Sean
Wojtanowicz, Todd R.
Sampathi, Bharat Reddy
Penev, Sofia
Bota, Robert
Case report: Chlorpromazine and deep venous thrombosis
title Case report: Chlorpromazine and deep venous thrombosis
title_full Case report: Chlorpromazine and deep venous thrombosis
title_fullStr Case report: Chlorpromazine and deep venous thrombosis
title_full_unstemmed Case report: Chlorpromazine and deep venous thrombosis
title_short Case report: Chlorpromazine and deep venous thrombosis
title_sort case report: chlorpromazine and deep venous thrombosis
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364570/
https://www.ncbi.nlm.nih.gov/pubmed/32742621
http://dx.doi.org/10.1108/MIJ-10-2019-0005
work_keys_str_mv AT reedmatthewjoseph casereportchlorpromazineanddeepvenousthrombosis
AT comeausean casereportchlorpromazineanddeepvenousthrombosis
AT wojtanowicztoddr casereportchlorpromazineanddeepvenousthrombosis
AT sampathibharatreddy casereportchlorpromazineanddeepvenousthrombosis
AT penevsofia casereportchlorpromazineanddeepvenousthrombosis
AT botarobert casereportchlorpromazineanddeepvenousthrombosis